
Pfizer and two subsidiaries will pay $345 million to escape antitrust litigation over an alleged scheme to gouge purchasers of the EpiPen, a lifesaving allergy treatment formerly made by a Pfizer unit and marketed by Mylan NV, according to a federal court filing in Kansas.
Featured News
Federal Judge Certifies NCAA Tennis Antitrust Lawsuit as Class Action
Jul 29, 2025 by
CPI
Two Senior DOJ Antitrust Officials Dismissed
Jul 29, 2025 by
CPI
AI Big Tech Faces Political Vetting Under Trump’s Executive Order
Jul 29, 2025 by
CPI
EU Technology Regulations Survive in US Trade Deal
Jul 29, 2025 by
CPI
Dairy Cooperatives Agree to $34.4 Million Settlement in Price-Fixing Case
Jul 29, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Surveillance Pricing
Jul 14, 2025 by
CPI
Should We Fear Personalized Pricing?
Jul 14, 2025 by
John Yun
Data and Price Competition: The Special Role of Information About Rivals’ Prices
Jul 14, 2025 by
Zach Y. Brown & Alexander MacKay
Surveillance Pricing: A Cautionary Summary of Potential Harms and Solutions
Jul 14, 2025 by
Ginger Zhe Jin, Liad Wagman & Mengyi Zhong
The Rise of Surveillance Pricing
Jul 14, 2025 by
Rebecca Kirk Fair, Alvaro Ziadi & Juan Carvajal